Skip to content

Released Mar 5, 2019, after the close

10-K filed Mar 5, 2019, 64 days after period end · 0001564590-19-006258

Q4 2018 · 10-K
Revenue$1.66M+61.7% vs Q4 2017+61.9% vs Q3 2018
Net Income-$16.03MN/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.25N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$16,741,000N/M
Operating Cash Flowderived-$11,020,000N/M
Free Cash Flowderived-$12,137,000N/M
Margins · derived
Operating margin-1007.9%+184.3 pt vs Q4 2017
Net margin-964.9%+251.9 pt vs Q4 2017

What the release said

The release

Same quarter

MetricQ4 2018Q4 2017Q4 2016Q4 2015
Revenue$1.66M$1.03M$1.03M$1.08M
Net Income-$16.03M-$12.50M-$7.94M-$7.45M
EPS Diluted-$0.25-$0.29-$0.21-$0.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR